Research Article

Gene Therapy (2005) 12, 579–587. doi:10.1038/sj.gt.3302441 Published online 13 January 2005

PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile

M A Croyle1,2, H T Le1, K D Linse2, V Cerullo3,4, G Toietta5, A Beaudet5 and L Pastore3,4

  1. 1College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, Austin, TX, USA
  2. 2The Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX, USA
  3. 3Dipartimento di Biochimica e Biotecnologie Mediche, University of Naples 'Federico II'
  4. 4CEINGE-Biotecnologie Avanzate, Napoli, Italy
  5. 5Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

Correspondence: Dr MA Croyle, College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, PHR 4.214D, 1 University Station #A1920, 2409 W. University Avenue, Austin, TX 78712, USA

Received 22 July 2004; Accepted 4 October 2004; Published online 13 January 2005.

Top

Abstract

Transgene expression from helper-dependent adenoviral (HD-Ad) vectors is effective and long lasting, but not permanent. Their use is also limited by the host response against capsid proteins that precludes successful gene expression upon readministration. In this report, we test the hypothesis that PEGylation of HD-Ad reduces its toxicity and promotes transgene expression upon readministration. PEGylation did not compromise transduction efficiency in vitro and in vivo and reduced peak serum IL-6 levels two-fold. IL-12 and TNF-alpha levels were reduced three- and seven-fold, respectively. Thrombocytopenia was not detected in mice treated with the PEGylated vector. Serum transaminases were not significantly elevated in mice treated with either vector. Mice immunized with 1 times 1011 particles of unmodified HD-Ad expressing human alpha-1 antitrypsin (hA1AT) were rechallenged 28 days later with 8 times 1010 particles of unmodified or PEG-conjugated vector expressing beta-galactosidase. Trace levels of beta-galactosidase (52.23plusminus19.2 pg/mg protein) were detected in liver homogenates of mice that received two doses of unmodified HD-Ad. Mice rechallenged with PEGylated HD-Ad produced significant levels of beta-galactosidase (5.1plusminus0.4 times 105 pg/mg protein, P=0.0001). This suggests that PEGylation of HD-Ad vectors may be appropriate for their safe and efficient use in the clinic.

Keywords:

helper-dependent adenoviral vectors, PEGylation, toxicology, readministration, immune response

Extra navigation

.

naturejobs

natureproducts


ADVERTISEMENT